Azrin NH, Holz WC (1966) Punishment. In: Honig WK (ed) Operant behavior: areas of research and application. Prentice-Hall, Englewood Cliffs, 380–447
Banks ML, Negus SS (2017) Insights from preclinical choice models on treating drug addiction. Trends Pharmacol Sci 38:181–194
Article CAS PubMed Google Scholar
Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonist. Pharmaceuticals 12:95
Article CAS PubMed PubMed Central Google Scholar
Bedini A, Di Cesare Mannelli L, Micheli L, Baiula M, Vaca G, De Marco R, Gentilucci L, Ghelardini C, Spampinato S (2020) Functional selectivity and antinociceptive effects of a novel KOPr agonist. Front Pharmacol 11: 188 10.3389
Bolanos CA, Garmsen GM, Clair MA, McDougall SA (1996) Effects of the kappa-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat. Eur J Pharmacol 317:1–8
Article CAS PubMed Google Scholar
Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aube J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9: ra117
Chan HCS, McCarthy D, Li J, Palczewski K, Yuan S (2017) Designing safer analgesics via mu-opioid receptor pathways. Trends Pharmacol Sci 38:1016–1037
Article CAS PubMed PubMed Central Google Scholar
Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63:316–347
Article CAS PubMed PubMed Central Google Scholar
Dunn AD, Reed B, Erazo J, Ben-Ezra A, Kreek MJ (2019) Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem Neurosci 10:3590–3600
Article CAS PubMed Google Scholar
Freeman KB, Naylor JE, Prisinzano TE, Woolverton WL (2014) Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology 231:2751–2758
Article CAS PubMed PubMed Central Google Scholar
Glick SD, Maisonneuve IM, Raucci J, Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147–152
Article CAS PubMed Google Scholar
Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M et al (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404–413
Article CAS PubMed Google Scholar
Huskinson SL, Platt DM, Brasfield M, Follett ME, Prisinzano TE, Blough BE, Freeman KB (2020) Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor agonists in male rhesus monkeys. Psychopharmacology 237:2075–2087
Article CAS PubMed PubMed Central Google Scholar
Huskinson SL, Platt DM, Zamarripa CA, Dunaway K, Brasfield M, Prisinzano TE, Blough BE, Freeman KB (2022) The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys. Pharmacol Biochem Behav 217:173394
Inan S, Huerta AT, Jensen LE, Dun NJ, Cowan A (2019) Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol 864:172702
Article CAS PubMed PubMed Central Google Scholar
Inui S (2015) Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol 8:249–255
Article PubMed PubMed Central Google Scholar
Jones MR, Kaye AD, Kaye AJ, Urman RD (2016) The emerging therapeutic roles of kappa-opioid agonists. J Opioid Manag 12:101–107
Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA et al (2019) Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J Pharmacol Exp Ther 371:487–499
Article CAS PubMed PubMed Central Google Scholar
Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193–200
Article CAS PubMed Google Scholar
Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S (2017) Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS ONE 12:e017899
Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, Muschamp JW, Cowan A, Mann M, Liu-Chen LY (2019) Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in κ opioid aversion. Neuropsychopharmacology 44:939–949
Article CAS PubMed Google Scholar
MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology 226:381–392
Article CAS PubMed Google Scholar
Mores KL, Cummins BR, Cassell RJ, van Rijn RM (2019) A review of the therapeutic potential of recently developed g protein-biased kappa agonists. Front Pharmacol 10:407
Article CAS PubMed PubMed Central Google Scholar
Nakao K, Mochizuki H (2009) Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (barc) 45:323–329
Article CAS PubMed Google Scholar
Negus SS, Bilsky EJ, Do Carmo GP, Stevenson GW (2010) Rationale and methods for assessment of pain-depressed behavior in preclinical assays of pain and analgesia. Methods Mol Biol 617:79–91
Article PubMed PubMed Central Google Scholar
Negus SS, Schrode K, Stevenson GW (2008) Micro/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386–399
Article CAS PubMed PubMed Central Google Scholar
Paton KF, Kumar N, Crowley RS, Harper JL, Prisinzano TE, Kivell BM (2017) The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran salvinorin B in mice. Eur J Pain 21:1039–1050
Article CAS PubMed PubMed Central Google Scholar
Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774–776
Article CAS PubMed Google Scholar
Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA et al (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biol Psychiatry 72:871–879
Article CAS PubMed PubMed Central Google Scholar
Rankovic Z, Brust TF, Bohn LM (2016) Biased agonism: an emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett 26:241–250
Article CAS PubMed Google Scholar
Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59–65
Article CAS PubMed PubMed Central Google Scholar
Townsend EA (2021) Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration. Psychopharmacology 238:1017–1028
Article CAS PubMed Google Scholar
Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology (Berl) 234: 2597-2605
Tsuji M, Takeda H, Matsumiya T, Nagase H, Narita M, Suzuki T (2001) The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci 68:1717–1725
Article CAS PubMed Google Scholar
Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320(1–13):10
Zamarripa CA, Naylor JE, Huskinson SL, Townsend EA, Prisinzano TE, Freeman KB (2020a) Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys. Psychopharmacology 237:1471–1480
Article CAS PubMed PubMed Central Google Scholar
Zamarripa CA, Pareek T, Schrock HM, Prisinzano TE, Blough BE, Sufka KJ, Freeman KB (2021) The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats. Psychopharmacology 238:3463–3476
Article CAS PubMed PubMed Central Google Scholar
Zamarripa CA, Patel TR, Williams BC, Pareek T, Schrock HM, Prisinzano TE, Freeman KB (2020b) The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone’s conditioned rewarding effects in male rats. Behav Pharmacol 31:792–797
Article CAS PubMed PubMed Central Google Scholar
Zhang Y, Kreek MJ (2020) Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL/6J mice. Neuropharmacology 176:108244
留言 (0)